Cervical cancer vaccine 'could cut deaths by two thirds'

A vaccine that blocks infection by four types of viruses could cut global deaths from cervical cancer by more than two thirds, its manufacturer says.

Merck & Co wants America’s Food and Drug Administration to approve its Gardasil vaccine against the two of those four types of human papillomavirus, or HPV, believed to be responsible for about 70% of cervical cancer cases.